Estradiol (MINIVELLE) - USA

IPR decision (Sep 10, 2018):

AIA Review	Filing Date	Institution Date	Petitioner	Patent No.	Final Written Decision
IPR2018-01119	05/18/2018	--	Mylan	9,833,419	Terminated-Settled

US  9,833,419 (Noven Pharmaceuticals, Inc.; Exp: 07/10/2028):

1. A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner, wherein the single adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug, wherein the adhesive polymer matrix layer has a coat weight of greater than 10 mg/cm.sup.2 and includes greater than 0.156 mg/cm.sup.2 estradiol, and the system achieves an estradiol flux of from 0.0125 to about 0.05 mg/cm.sup.2/day, based on the active surface area.